INTRODUCTION 2.1 The Need for high-throughput cell separation technologies for clinical dia2nostics and therapeutics
High throughput cell separation technologies are growing increasingly important for clinical diagnostics and therapeutics. The sensitivity of new molecular diagnostic techniques means that the molecular results of contaminating cell types can at best compromise the sensitivity ofthe measurement. At its worst, the presence of contaminating cell types can obscure or even reverse the diagnostic result.
The problem is especially important in clinical applications such as minimal residual disease monitoring. For example, in metastatic breast cancer, the tumor cells may be present in only a few cells per million in the bone marrow or peripheral blood ofthe patient. To adequately sample the patient's bone marrow or peripheral blood requires statistical sampling of at least several hundred million cells. This would require many hours or even days by conventional flow cytometry and at conventional cell sorting speeds.
The importance of tumor purging has recently been demonstrated by gene marking experiments (Brenner, 1993; Brenner et al., 1995) . These experiments show that failure to purge tumor cells from autologous transplants may results in killing an immuno-compromised cancer patient with his or her own tumor cells.
Detection and Isolation of human fetal cells from maternal blood fore fetal cell diagnostics
The detection and isolation of fetal cells from maternal blood for subsequent genetic analysis has been a dream since the early 1970's. The reality has been considerably more sobering in terms ofthe difficulty and the lack of good probes for fetal cells. Most fetal cells have been detected either on the basis ofthe presence ofpaternal HLAantigens or on the basis of differentiation antigens expressed on early nucleated erythrocytes not normally found in large numbers in the adult blood. But the sobering reality has been that it is virtually impossible to make even a very good monoclonal antibody against HLA antigens that does not have a high rate of false positives when trying to label rare fetal cells of typical normal frequencies of 1 06 or less in a pregnant mother' s blood. Likewise, it is difficult to use differentiation antigens on nucleated erythrocytes without a high-rate of false-positives due to the increased generation of nucleated erythrocytes in the stressed bone marrow of pregnant women. Further complicating the problem is the possible existence of circulating lymphocytes from earlier pregnancies that may persist for many years. In this paper we describe new technologies and methods that may help make the overall goal more reasonable.
The isolation of a true human fetal cell from maternal blood is difficult in the case of a grossly abnormal fetal cell (e.g. a trisomy 13 , 18 or 21) or in the case where the genetic disease is not X-linked (e.g. in the female fetus). To date most flow cytometry/cell sorting of fetal cells has looked only for trisomies and the presence of male fetal cells bearing the Y-chromosome. With the near completion ofthe Human Genome Project and a subsequent analysis of the range of "normal" polymorphisms, it should be possible to take advantage of DNA microarrays to screen for hundreds or even thousands ofpossible human mutations leading to diseases not detectable at the gross abnormality level.
High-throughput screening of libraries
High-throughput screening of libraries containing recombinant DNA, oligonucleotides, or amino acid sequences has great promise for therapeutics. One example to be discussed in this paper is that ofproduction of recombinant vaccines by high-throughput screening of large numbers of recombinant clones of human immunoglobulin recognition sequences within a bacterial library. This therapeutics application requires very high-speed analysis and cloning of bacterial clones containing the proper immunoglobulin recognition sequence against the antigen of interest.
2.4
The importance of separating pure cells or cell subpopulations for subseQuent molecular analyses by single-cell DNA PCR and for gene expression microarray analysis When purified rare cells can be obtained from heterogeneous cell mixtures such as bone marrow (in the case of MRD monitoring) or from maternal blood (for fetal cell diagnostics), specific gene mutations can be readily diagnosed by single-cell PCR and single-cell DNA sequencing.
For example, we have previously shown that in the case of fetal cell diagnostics, we could successfully identify and isolate non-grossly abnormal fetal cells on the basis of HLA type using monoclonal anti-HLA antibodies. But even with an excellent quality monoclonal antibody of high-specificity, we were able to obtain separated cells of only 10 percent purity. In these experiments we were able to isolate from the blood of a mother in her ninth week of pregnancy a sample often cells that contained a single fetal cell on the basis ofPCR amplification ofthe DNA of those ten cells with subsequent HLA typing using allele-specific oligonucleotides (ASO) as shown in Figure X in the Results section. This led us to work on improved single-cell PCR amplification methods as well as introducing the concept of multi-tube, single cell PCR that no longer requires that the molecular selection probe (in this case a monoclonal antibody) be perfect in its selection of the rare cell of interest. The selection probe or probes need only be good enough to enrich enough that the number of single cells sorted for subsequent single-cell PCR and molecular diagnosis be small enough to be reasonable and cost-effective.
While further work on this fetal cell diagnostics application was halted prematurely through an interruption of research funding and a laboratory move, we were able to pursue this concept in a different application, namely the detection of metastatic breast cancer cell clones containing tumor suppressor gene mutations that allow these cells to escape detection by the immune system. In feasibility experiments involving defines cell mixtures of human breast cancer cell lines with well-defined tumor suppressor gene mutations and human bone marrow cells, we were able to demonstrate detection of these cells at a frequency of 106 with a cell sorting purity of 30 percent using the singlecell, multi-tube cell sorting concept. Furthermore, we were able to sort single tumor cells and demonstrate the feasibility of single-cell DNA sequencing of a single base pair deletion in the PTEN tumor suppressor gene of these cells.
Attempts to perform single cell RT-PCR met with limited success. While we could routinely perform such analyses on 5 or more cells, single cell results, while possible, were not routinely reproducible. This led us to consider other alternatives such as gene expression microarrays. Microarrays are generally used for applications involving a minimum of approximately one-halfmillion cells. However, pre-amplification methods are being developed by other groups to allow microarray analyses of a few thousand cells. In preliminary work we were able to perform a gene expression microarray analysis on 1000 cells, but all genes were not amplified equally as seen by comparison with microarray analyses of conventional, unamplified cDNA from cells. Further work will involve more linear amplification methods and more sensitive detection methods. However, we were able to demonstrate in these experiments the importance of analyzing purified cell subpopulations rather than cell mixtures. As seen in Figure Y of the Results section, the gene expression profiles of cell mixtures roughly follow the expected result of a superposition ofthe gene expression profiles ofthe different cell types present according to their relative abundance.
METHODS
3.1 Methods for high-throughput flow cytometry/cell sorting Over the past twenty years our laboratory has developed a large number of instrument hardware and software technologies and methodologies for dealing with the high-throughput processing of cells and other objects (Cupp et al. 1984 ; Leary et at., 1991; Leary et at., 1996b; 1997b) as well as a wide variety ofcell labeling and manipulation techniques for "rare-event analysis", namely the analysis and sorting of cell subpopulations with frequencies less than 0. 1 percent (for a reviews see Leary, 1994; Leary, 2000) . More recently, we have extended these procedures to the realm of "ultra-rare" cells, namely those cell subpopulations of frequencies less than 0.00 1 percent (Leary et at., 1995; 1996; 1998a; 1998b; 1999a; 1999b; 2000a; 2000b; Hokanson et at., 1999) . To accomplish this level of high-throughput cell processing we have not only developed a very high-speed flow cytometers/cell sorter, but also given it a sophisticated hardware/software, two-stage cell classification and sorting system capable of using real-time multivariate statistical classifications, including measures of the probability of correct cell classification (also referred to sometimes as "penalties of misclassification")(for patents see 1998 and 1996) . Going faster alone does not due the job if one generates huge numbers of false-positives. Rare cell sampling statistics is also an important issue that we have studied at some length and for which we have developed new rare-cell sampling statistical techniques (Rosenbtatt et at., 1997).
The result ofthese efforts has been the development ofa high-throughput cell sorter ( Interestingly cell sorters are inherently much more efficient at higher cell processing speeds as long as the instrument deadtime, the time period that it takes for an instrument to process one cell and be ready to measure the next cell, can be kept very low. The deadtime first stage of our 2-stage cell processing system is less than 2 microseconds as compared with typical deadtimes of 1 0-1 5 microseconds on most commercial cell sorters and approximately 5 microseconds on the fastest commercial cell sorter presently available. A detailed discussion of the importance of instrument deadtime from the viewpoint of queuing theory is beyond the scope of this paper but has been clearly and simply discussed in two book chapters (Leary, 1994; Leary, 2000) . A very simple illustration that makes the point obvious is show n in Figure 2 .
Concept of high-throughput "enrichment sorting" 4. RESULTS
Development of instrumentation for high-throughput flow cytometry and cell sortin2
The development of high-speed cell sorters suitable for detection and isolation of rare cells involves a number of factors including instrumentation, data analysis Software, and cell preparation methods (for a general review see Leary, 1994 ). We have previously described our development of instrumentation for high-throughput flow cytometry and cell sorting (Leary et at., 1995; 1996; 1998; Leary, Corio, and McLaughlin 1993; 1998, Corio and 1996 , for a recent review see Leary, 2000) . Briefly in terms of the instrumentation, we have developed a 2-stage, real-time, cell classification system for high-speed, high-resolution cell sorting as shown in Figure 3 Patent 5,204,884 (1993) us. Patents 5,199,576 (1993) and 5, 804 ,143 (1998) and 5,550,058 (1996) non-rare cell, "not -of-interest" 0 (e.g. original frequency a 99. 999 %) rare cell, "of interest" (e.g. original frequency : 0.001 %) Figure 2 : Cell sorters are much more efficient at very high throughput speeds in terms of the enrichment factor from the original rare cell concentration to the final sorted rare cell concentration. In this concept figure a cell of original frequency of 1 O (1 rare cell per 1 00,000 total cells) can be sorted at 100,000 cells/sec with a sorter capable ofgenerating 33,000 droplets/sec. A high-speed first-pass sort enrichment ofmore than 30,000-fold, based on up to 3 rare parameters and 5 additional total parameters, can be attained. Sorted cells can then be re-sorted to any desired purity, based on the quality ofthe selection probes. The first stage processes incoming signals with a deadtime ofless than 2 microseconds, counting all cells and classifying them into "positives", "negatives" or "not-sures". The "positives" and "not-sures" are then sent to a second-stage system that uses more complex multivariate statistical functions to better classify these cells and to provide a measure of the degree of potential misclassification. Detection of mutations in breast cancer tumor suppressor genes by hi2h-throughput flow cytometry, sin2le ji sorting, and single-cell sequencing
An example ofrare tumor cell detection we have previously described (Leary et at., 1999) is shown in a model system in Figure 4 . A rare tumor cell clone was mixed with a human T -cell line at a frequency of 1 O. A defined cell mixture of CEM/C7 (human T-cells) and MCF-7 cells (ATCC Number: HTB-22, Name: MCF-7 (human breast carcinoma cells)) was constructed to yield a frequency of 1 6tumor cells for flow cytometry and cell sorting. The cells were then analyzed on the basis of cytokeratin positive fluorescence and for negative labeling with CD45 are shown below:
We then tested for sort recovery and purity in the case ofa defined cell mixture ofMCF-7 and CEM-C7 cells. We used DNA HLA-DQalpha typing ofthe MCF-7 cells [1 . 2, 4 ] and the CEM/C7 cells [1 .2, 1 .3] to see our efficiency of successful selection of tumor cells. The primers and oligo dot blot probes used in these studies are as described in Leary et at., 1999b. Since the amount ofPCR-amplified DNA from a single cell is too small to be seen by conventional ethidium bromide staining ofthe PCR products on a gel, enzymatic amplification techniques must be used. One such technique we have used is ECL ( Enhanced Chemiluminescence; Amersham Life Science, Catalog No. RPN 3021) whereby Southern blotting is performed with enzymatically labeled complementary sequence oligonucleotide ("oligo") probes. An enzymatic reaction gives rise to chemiluminescence that can then be detected on X-ray film, but without the hazards and disposal problems ofradioactive probes. ECL provides an enzymatic amplification factor of approximately 1000 times, permitting detection ofPCR products from single cells (Leary et at., 1999b).
4.3 Singte-cetl DNA seiuencin2 resutts from TA ctoning:
As we described previously (Leary et at., 1999b; Leary Ct at. 2000a) DNA sequencing of sorted single tumor cells can be performed. We sorted single cells with several mutations, including the BT-549 cells which have a single base pair mutation in the so-called PTEN gene, a tumor suppressor gene that has been previously described (Li et at., 1997) . A clone of BT-549 cells was analyzed by flow cytometry and sorted into single PCR tubes for subsequent analysis by PCR and TA cloning. The DNA from the PTEN gene region of sorted single cells was amplified by PCR and cloned into a TA cloning vector. The vector was then amplified by growth in host E. Coli bacterial cells, and the plasmid DNA was isolated and purified. This purified plasmid DNA containing the PTEN gene sequences from sorted single cells was then analyzed on a DNA sequencing instrument. A typical DNA sequencing result from a single sorted BT-549 cells is shown in Figure 4B . Cells without the mutated sequence show normal PTEN gene sequences (data not shown).
An alignment analysis of the above sequence data reveals a single base pair deletion at nucleotide 61 of exon 8 of PTEN gene indicative of the PTEN mutation present in these BT-549 cells.
cett diagnostics
One approach to this challenging problem is to use very high-throughput flow cytometry to obtain adequate sampling statistics (e.g. 50 rare cells or more) and sophisticated cell classification algorithms to reduce the number of false-positives. By using single-cell, multi-tube cell sorting and PCR amplification techniques, perhaps with single-cell DNA sequencing of particular genes of interest, neither the selection markers nor the sorting has to be perfect. It only has to be good enough to be practical.
Shown in Figure 5 is a clear illustration ofthe utility of a high-throughput flow cytometric analysis followed by a single-cell, multi-tube sort with subsequent single-cell PCR analysis. Once the rare fetal cells from a 9-week pregnant mother were identified on the basis of erythroid-lineage monoclonal antibody markers and the presence of a nucleus using 7-amino-actinomycin D, 10 putative fetal cells were isolated by high-resolution single-cell sorting and analyzed at the DNA level using allele-specific oligonucleotides. Results in clearly show that in the 10-cell sort at least one of the cells had to be fetal as based on subsequent HLA typing of the mother, father and of that fetus after birth.
Several examples of rare cell analyses as performed in this author's laboratory illustrate different strategies for flow cytometric analysis and/or sorting of rare cell subpopulations. These strategies were formulated for specific situations and subject to subsequent characterizations of sorted rare cells by different techniques. As an example of results that can be obtained with a high-speed cell sorter, cells were processed in our laboratory at 85,000 cells/sec for 3-color immunofluorescence using two positive (but not fetal-cell unique) selection markers (CD34 and CD71) and one negative selection marker (CD45). This application used for selection ofhuman fetal cells from the blood of a pregnant woman involves flow cytometric analysis of early erythroid cells (highly enriched but not specific for rare fetal cells) in unlysed maternal whole blood (processed at a concentration of approximately 5x108 cell/ml). Data are shown in Figure 5 (9) . Results dramatically illustrating the importance ofpositive and negative selection marker strategies is shown in Figure 5 . The labeling strategy is shown in Figure 5A . The negative selection gate is shown in Figure 5B . As shown by comparing Figure 5Cwith its isotype control in Figure 2E it would be difficult or impossible to sort out rare cells of interest due to the high non-specific background. However, when only one negative selection marker, in this case CD45 coupled to a phycoerythrin-cyanine-5 (PE-Cy5) tandem-conjugate energy transfer probe which labels mature maternal leukocytes as well as dead/damaged and non-specifically binding cells, is used the situation changes dramatically. Comparison of Figure 5D and Figure 5F reveal an easily identifiable subpopulation of "putative" fetal cells that can be sorted. The boxed region of interest in Figure 5E contains a calculated frequency of 1 .8 x 1 O' based on a total sample size of 108 cells. Finite sampling theory gives the 95%confidence range ofthe rare cell frequency to be between 1.8 x iO-7 and 2.0 x i07. To have 95% probability of being able to sample (and sort in the absence of other possible losses) 10 cells from a sample aliquot containing 108 cells would require us to process at least 71% of the sample. Such calculations can obviously be used to determine how much sample can be first analyzed to set sorting gates while still allowing for enough rare cells to remain for subsequent sorting. This application also shows why it is difficult to use depletion cell separation technologies (e.g. affinity columns and magnetic bead sorting). While it is theoretically possible to allow sorting on the basis of levels of antigen expression with these technologies, these sorting levels are much more difficult to control. In the sample shown in Figure 5 , approximately half of the fetal cells are CD45 dim rather than CD45 negative. It is also very difficult to recover cells from affinity columns or through magnetic sorting devices when there may be only a few rare cells although such methods are useful as cell isolation or pre-enrichment procedures to obtain larger numbers of not very rare cells (e.g. 1 % subpopulations) when the total number of rare cells available is large (greater than a few thousand cells). Multiple sets of PCR primers can be used on single cells to simultaneously confirm the identity of the cell and to check for specific gene sequence abnormalities. Rare cell subpopulations should always be thought of as "putative" until the rare cells are sorted and characterized, preferably by unequivocal molecular means such as PCR-amplified cell specific DNA sequences. While tandem conjugate energy transfer probes are extremely useful for multicolor fluorescence flow cytometric experiments, they can sometimes lead to problems when cells are dimly positive (in this case for PB) due to energy transfer "leakage". An energy transfer probe that "leaks' fails to achieve energy transfer and gives off donor rather than aèceptor fluorescence (in this case it would falsely give off PB rather than Cy5 fluorescence). In that case it is difficult to distinguish between cells with leaky energy transfer probes and trues fluorescence positive cells (in this case PB positive cells). However, even somewhat leaky energy transfer probes can still be used successfully as negative selector probes since any cells which are positive for the donor fluorescence will also be positive for acceptor fluorescence and all acceptor fluorescence positive cells are eliminated. This is analogous to the situation of not worrying about propidium iodide (P1) fluorescence in dead/damaged cells spectrally overlapping with fluorescein fluorescence since all PT-positive cells will be gated out of the distribution. This is why we have used the tandem conjugate probe on the negative selector in the above example.
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To reveal the true identity of sorted rare cells it is best to do so at the DNA level. In the case of high-throughput fetal cell diagnostics, one can sort the cells of interest and then DNA type the cells on the basis of maternal and paternal HLA-DQ alpha haplotypes ( Figure 6 ). Using PCR primers as shown in Figure 6B and allele-specific oligonucleotide (ASO) analysis ( Figure 6A ), we typed 10 sorted putative fetal cells. By comparing the maternal and paternal DNA types as shown in Figure 6C we were able to show that while most of the putative fetal cells were really maternal cells, at least one of the cells had to be fetal since it had the DNA type of the father. The identity of the fetal cells obtained by high-throughput sorting was confirmed by DNA typing the baby after it was born. As the last example we describe briefly our newest HTS application -the screening of bacterial-pathogen complexes for production of recombinant vaccines against unknown pathogens. Our collaborators, Drs. George Georgiou and Brent Iverson have developed an expression library whereby all of the human immunoglobulin gene recognition epitopes are expressed in a bacterial library (Georgiou et al., 1997) . By then painting unknown pathogens with a fluorescent dye, fluorescent bacterial-pathogen complexes can then be processed by HTS and cloned to single-cell level as shown in Figure 7: Bacterial clones biding the unknown pathogen can then be rapidly grown for use in production of a recombinant vaccine. In order to be practical the total cell throughput must be at least 100,000 cells/sec, and rates of 300,000 cells/sec would be even more reasonable. This requires a very HTS instrument, beyond the realm of commercial instruments. We are now making modifications to our high-speed cell sorter that should permit analysis rates of greater than 300,000 cells/sec and practical sorting rates in excess of 100,000 cells/sec with single-cell cloning capability.
The importance of HTS for gene expression microarray analyses
In the earlier examples of HTS we showed single cell, molecular characterization ofthe sorted cells. At present this is not possible to do with gene expression microarrays. In fact, due to the low sensitivity ofthe current generation of microarrays and their detection schemes, several hundred thousand cells are required for each microarray. This represents a significant barrier to the pursuit of many biological and clinical problems where this number of cells of a given cell subpopulation are simply not available. Nonetheless it is important to deliver purified cell subpopulations to the microarray as shown in Figure X . Mixtures of cells on microarrays produce, as expected, the superposition of gene expression profiles of all the cell subpopulations present according to their relative amounts. Some times one can be lucky in that some genes are expressed only in certain cell types. In that case one can typically see these genes from a 10 percent cell subpopulation. But when different cell subpopulations People in the laser capture microdissection field have been struggling with this problem for some time. They have developed a number ofpre-amplification methods to expand the number oftarget molecules before microarray analysis (Eberwine, 1996; Gonzalez et al., 1999) . But it is very difficult to amplify the mRNA from small numbers of cells without distorting the relative gene expression profile as compared to what it would be without the preamplification. HTS can present as many purified cell types to a microarray as possible, but there may be fundamental limits posed by the biology. The solution to this fundamental problem is a mixture of improvements in microarray sensitivity so that fewer cells are needed, and pre-amplification methods that expand all genes equally in a linear and reproducible fashion. HTS is also important since RNA degradation can be a significant problem. Since RNA rapidly degrades, and specific mRNAs turn over in minutes or hours, cell separation process must be very rapid. Cell fixation may be one possible solution to the rapid degradation of mRNA problem (Goldsworthy et al., 1999) They found that rapid fixation of frozen tissue in 70% ethanol produced the best results, but acceptable results were obtained with a variety of other fixatives.
CONCLUSIONS
High throughput technologies, including high-speed flow cytometry and cell sorting, are important to clinical diagnostics and therapeutics. Post-separation molecular characterization technologies such as single-cell PCR and single cell sequencing and gene expression microarray analyses depend on the delivery of purified cells or cell subpopulations. Otherwise these molecular characterization technologies superimpose the DNA sequence or gene expression profile patterns ofthe different cell types present. In particular, gene expression profiles from microarray analyses performed on mixtures of cell types, cell cycle and cell differentiation stages, activated and non-activated cells are at best compromised in value, and at worst of little value.
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